SLT 0.00% 0.7¢ select exploration limited

credibility established

  1. 298 Posts.
    Until today, I like many others, saw the major risk factor with SLT being their ability to do a commerical deal, and along the lines of the numbers they expected as documented in the Clear Focus report.

    They said what they would do and they did it! And well within the timeframes announced. This increases my confidence that they will shortly do the Hep A, which is twice the size of Hep E (as per Clear Focus report). This should put them in the black and all set for the big one - Hep C.

    With the Hep E deal announced, and the positive outlook that they will do the Hep A, rapid dev of Hep C, ... this has become IMO an undervalued stock.

    I cannot understand why it is still seeing the 80's range. Seems to me to be a sleeping giant.
 
watchlist Created with Sketch. Add SLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.